Example: marketing
ACTEMRA EUA Patient Fact Sheet
Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of ACTEMRA® (tocilizumab) for . Coronavirus Disease 2019 (COVID-19) You are being given this Fact Sheet because your healthcare provider believes it is necessary to provide you or your child with ACTEMRA for the treatment of coronavirus disease 2019 (COVID-19).
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION ACTEMRA …
www.gene.com162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response Patients at or above 100 kg weight 162 mg administered subcutaneously every week Giant Cell Arteritis (2.2) Recommended Adult Subcutaneous Dosage: The recommended dose of ACTEMRA for adult patients with GCA is 162 mg
OCREVUS Prescribing Information - Genentech
www.gene.comHepatitis B Virus Screening Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBVtests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV
XOLAIR Prescribing Information - Genentech
www.gene.comCorticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of XOLAIR therapy. (5.4) Eosinophilic Conditions: Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or Fever, Arthralgia, and Rash: Stop XOLAIR if patients develop signs and sickness. (5.6)
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.gene.com1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TAMIFLU safely and effectively. See full prescribing information for
Initial dose of 4 mg/kg over 90 minute IV infusion, …
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION The …
www.gene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for
Reference ID: 4212951 - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information …
Valcyte Master USPI - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VALCYTE ® safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION - Genentech
www.gene.com2 FULL PRESCRIBING INFORMATION WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Herceptin administration can …
HIGHLIGHTS OF PRESCRIBING INFORMATION The dose for …
www.gene.comfull prescribing information warning: fatal infusion reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive
Related documents
Pfizer-BioNTech COVID-19 Vaccine: 12 Years of Age and ...
www.cdc.gov* Inform recipients, especially males 12 through 29 years of age and their parents/legal representative (when relevant) of the possibility of myocarditis or pericarditis following receipt of mRNA ... copy of the current Fact Sheet for Recipients and Caregivers. ... Vaccination providers should observe patients after ...
COVID-19 Monoclonal Antibody Infusion Referral Form DATE:
www.mcleodhealth.orgConfirm that patient has received the EUA Fact Sheet for Patients and Caregivers. If hard copy cannot be provided it will be provided at the infusion site but please check box below to confirm patient understands and has consented. “I verbally provided the patient/caregiver the information contained in the COVID-19 monoclonal antibody
Fact Sheet for Patients And Parent/Caregivers remdesivir
doh.sd.gov1 Fact Sheet for Patients And Parent/Caregivers . Emergency Use Authorization (EUA ) Of Remdesivir For Coronavirus Disease 2019 (COVID-19) You are being given a medicine called remdesivir for the treatment of coronavirus disease 2019 (COVID-19). This